Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis

World Journal of Gastroenterology

Volumn 11, Issue 2, 2005, Pages 228-231

  Nan, Ke Jun ^a   Ruan, Zhi Ping ^a   Jing, Zhao ^a   Qin, Hai Xia ^a   Wang, Hong Yan ^a   Guo, Rui ^a   Xu, Rui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell proliferation; Fragile histidine triad protein; Hepatocellular carcinoma

Indexed keywords

CYCLINE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NICK END LABELING; PROTEIN EXPRESSION; TISSUE SECTION;

EID: 12344319159     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i2.228     Document Type: Article

References (30)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597
2. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392
3. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60: 18-21
4. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 1996; 93: 895-899
5. Moms GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989; 264: 13856-13864
6. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-294
7. Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001; 182 81-88
8. al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 1993; 71: 1954-1959
9. Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002; 181-182 471-474
10. Park YN, Chae KJ, Kim YB, Park C, Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001; 92: 2733-2738
11. Hino N, Higashi T, Nouso K, Nakatsukasa H, Tsuji T. Apoptosis and proliferation of human hepatocellular carcinoma. Liver 1996; 16: 123-129
12. Paiva C, Oshima CT, Lanzoni VP, Forones NM. Apoptosis, PCNA and p53 in hepatocellutar carcinoma. Hepatogastroenterology 2002; 49: 1058-1061
13. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998; 58: 1804-1807
14. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 2000; 60: 1049-1053
15. Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V, Sculier JP. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir 2003; 21: 753-758
16. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K, Huebner K, Croce CM. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000; 60: 1177-1182
17. Rocco A, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 2003; 129: 84-88
18. Andachi H, Yashima K, Koda M, Kawaguchi K, Kitamura A, Hosoda A, Kishimoto Y, Shiota G, Ito H, Makino M, Kaibara N, Kawasaki H, Murawaki Y. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br J Cancer 2002; 87: 441-445
19. Takizawa S, Nakagawa S, Nakagawa K, Yasugi T, Fujii T, Kugu K, Yano T, Yoshikawa H, Taketani Y. Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer. Br J Cancer 2003; 88: 1213-1216
20. Fouts RL, Sandusky GE, Zhang S, Eckert GJ, Koch MO, Ulbright TM, Eble JN, Cheng L. Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer 2003; 97: 1447-1452
21. Skopelitou AS, Mitselou A, Katsanos KH, Alexopoulou V, Tsianos EV. Immunohistochemical expression of Fhit protein in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with conventional clinicopathologic parameters. Eur J Gastroenterol Hepatol 2003; 15: 515-523
22. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-1624
23. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5‴-P1, P3-triphosphate hydrolase. Biochemistry 1996; 35: 11529-11535
24. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-13776
25. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Roster A, Blackburn GM, Siprashvili Z, Croce CM, Huebner K, Brenner C. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA 1998; 95: 5484-5489
26. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, Ishii H, Vecchione A, Kuroki T, Bieganowski P, Pace HC, Huebner K, Croce CM, Brenner C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA 2003; 100: 1592-1597
27. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001; 61: 4827-4836
28. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333-3339
29. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489-8492
30. Gopalakrishnan VK, Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatology 2003; 3: 293-302